Abstract
A case of a 69-year-old woman with myelofibrosis presenting with non-small cell lung cancer was reported at Sotiria General Hospital in Athens. She was administered bevacizumab infusions biweekly and a great decrease in the number of her white blood cells was observed. Such low levels of white blood cells had never been reached in the past, when she was receiving hydroxyurea.
MeSH terms
-
Aged
-
Angiogenesis Inhibitors / administration & dosage*
-
Antibodies, Monoclonal / administration & dosage*
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Carcinoma, Non-Small-Cell Lung / blood
-
Carcinoma, Non-Small-Cell Lung / blood supply
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Drug Administration Schedule
-
Female
-
Humans
-
Hydroxyurea / therapeutic use
-
Infusions, Parenteral
-
Leukocyte Count
-
Lung Neoplasms / blood
-
Lung Neoplasms / blood supply
-
Lung Neoplasms / drug therapy*
-
Primary Myelofibrosis / blood
-
Primary Myelofibrosis / drug therapy*
-
Treatment Outcome
Substances
-
Angiogenesis Inhibitors
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bevacizumab
-
Hydroxyurea